Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) have received an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued a report on the stock […]
Vaxcyte (NASDAQ:PCVX – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Analyst Recommendations This is a summary of recent […]
Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Analysts at Cantor Fitzgerald lifted their FY2023 EPS estimates for shares of Vaxcyte in a report released on Wednesday, August 9th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($3.05) for the year, up from their prior estimate of ($3.15). […]
Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Cantor Fitzgerald increased their FY2023 EPS estimates for shares of Vaxcyte in a report released on Wednesday, August 9th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings per share of ($3.05) for the year, up from their previous forecast of ($3.15). The consensus […]
Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) – Leerink Partnrs cut their Q3 2023 EPS estimates for Vaxcyte in a research report issued on Sunday, August 13th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn ($0.73) per share for the quarter, down from their previous estimate of ($0.70). The consensus estimate for […]